Barter - Figure 19 - Off-target torcetrapib Text

This Figure lists the off-target (non-serum lipid) effects seen with torcetrapib therapy in the ILLUMINATE trial. Given such an extensive list, it seems likely that the adverse outcome in ILLUMINATE may – stressing “may,” because trials don’t give mechanisms – may have been the consequence of an off-target pharmacology of torcetrapib, ie, possibly unrelated to CETP inhibition. Is this plausible (see next Figure)?

Barter P. J Clin Lipidol. 2011; 5(6).